André Albergaria and Bárbara Macedo from the i3S Research and Innovation Unit (RIU) recently attended a course titled “From Clinical Trial to Therapeutic Access” at INFARMED-National Authority of Medicines and Health Products. The invitation to join this course was extended by Isabel Borba Vieira, Non-clinical Pharmacotoxicology Assessor at INFARMED, who took part in last year’s Roundtable discussion on “The challenges surrounding translation in Molecular Bioengineering” organised by RIU during the MOBILIsE Launch Event at i3S.
This initiative was part of the MOBILIsE efforts to capacitate i3S members and foster closer ties between academic/translational research, regulatory paths and clinical research practice. Alongside strengthening collaboration with INFARMED, their participation in the course provided them with updated knowledge on Regulatory Evaluation of human medicines as well as health products, advanced therapies and medical devices. This knowledge update is crucial for offering more effective support to i3S researchers, facilitating significant advancements in the clinical application of their knowledge-intensive products and healthcare market entry paths, involving relevant stakeholders in valorisation, regulatory clarification, and also in promoting industry-academic-clinic R&D cooperative strategies in order to fulfil clinical and healthcare needs.
